Business Operations:

Sector: Healthcare
Industry: Medical Distribution

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Revenue projections:

HSIC's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio	1.319000
forwardPE	14.188053
debtToEquity	80.733000
earningsGrowth	0.171000
revenueGrowth	0.067000
grossMargins	0.313190
operatingMargins	0.057550
trailingEps	3.460000
forwardEps	5.993070

HSIC's current ratio is 1.319, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as HSIC should not face any issues meeting its short-term liabilities with available resources.
Henry Schein, Inc.'s Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
HSIC's high debt-to-equity ratio indicates that the company is heavily leveraged. This suggests a significant reliance on debt to finance its operations, which could expose the company to higher financial risks if its cash flow or profitability decreases.
Henry Schein, Inc.'s forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

HSIC's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

There were 6 HSIC sales transactions, at market price of 78.91333389282227.There were 2 purchases of HSIC stock, with market price of 67.44499969482422.The increased selling at Henry Schein, Inc.'s current price levels points to potential future declines. If this selling trend persists, the stock could face more downward pressure, suggesting investor pessimism about its future performance.

Recommendation changes over time:

The analysts' recent buy bias for HSIC indicates strong confidence in the stock's future performance. This could encourage more investors to view HSIC as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.